广生堂：公司生产经营一切正常

Core Viewpoint - The company Guangshentang (300436) stated that the U.S. tariff policy on pharmaceuticals has not materially affected the research and development progress of its drug GST-HG141, and that its production and operations are normal [1] Group 1 - The company management remains focused on its core business and is steadily advancing the research and development of innovative hepatitis B drugs [1]